3D Medicines Inc
01244
Company Profile
Business description
3D Medicines Inc is a commercial-stage biopharmaceutical company engaged in the research and development of oncology therapies for cancer patients, especially those who require long-term care. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China.
Contact
No. 3 and No. 5, Laiyang Road
Shandong
Qingdao
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
191
Stocks News & Analysis
stocks
Strong result for ASX insurer but not the new norm
Stellar first half profits but increasing competition will lower future rate increases.
stocks
Eli Lilly earnings: Weak Orforglipron obesity data weighs down a strong quarter
With today’s share drop, we think Lilly stock looks fairly valued.
stocks
Solid 2025 for A-REIT but development activity will weigh on 2026
Positive news for income investors as yield exceeds 5%.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,117.60 | 41.00 | 0.45% |
| CAC 40 | 7,698.52 | 44.48 | -0.57% |
| DAX 40 | 24,081.34 | 81.52 | -0.34% |
| Dow JONES (US) | 43,923.72 | 251.89 | -0.57% |
| FTSE 100 | 9,129.71 | 33.98 | 0.37% |
| HKSE | 24,906.81 | 47.99 | 0.19% |
| NASDAQ | 21,355.93 | 94.10 | -0.44% |
| Nikkei 225 | 41,820.48 | 761.33 | 1.85% |
| NZX 50 Index | 12,911.86 | 67.23 | 0.52% |
| S&P 500 | 6,366.28 | 23.17 | -0.36% |
| S&P/ASX 200 | 8,844.80 | 37.70 | 0.43% |
| SSE Composite Index | 3,647.55 | 12.42 | 0.34% |